コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of cell fate (e.g. LMO2 which is involved in acute leukaemia).
2 post-HSCT survival outcomes in patients with acute leukaemia.
3 th a special consideration for children with acute leukaemia.
4 2(-/-)Fancd2(-/-) mice spontaneously develop acute leukaemia.
5 years or over who underwent a transplant for acute leukaemia.
6 in a T cell line derived from a childhood T-acute leukaemia.
7 have improved the outlook for patients with acute leukaemia.
8 ept for patients enrolled in hospice or with acute leukaemia.
9 ble to near-term evaluation in patients with acute leukaemia.
10 ast cancer), and chemotherapy with increased acute leukaemia.
11 on of an aggressive and fully transplantable acute leukaemia.
12 ns in infant and secondary treatment-related acute leukaemias.
13 lving the RUNX1 gene are frequently found in acute leukaemias.
14 ocations occur in man at chromosome 11q23 in acute leukaemias.
15 erent partner genes in a proportion of human acute leukaemias.
16 slocation in T cells prior to development of acute leukaemias.
17 romosomal translocations in childhood T cell acute leukaemias.
18 gnancies is generally poor, particularly for acute leukaemias.
20 fered to patients receiving chemotherapy for acute leukaemia and high dose chemotherapy for solid tum
21 ese findings identify a dependency factor in acute leukaemia and suggest a mechanistic rationale for
22 Outcomes of 503 children (<16 years) with acute leukaemia and transplanted with umbilical cord blo
23 to treat a wide array of diseases, including acute leukaemias and congenital blood disorders, but obt
24 KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas
25 t the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19
26 eral framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-
27 We have analysed PTEN in a series of primary acute leukaemias and non-Hodgkin's lymphomas (NHLs) as w
28 ic alterations that drive the development of acute leukaemias and other haematopoietic diseases, it h
29 are the most common genetic abnormalities in acute leukaemia, and congenital mutations in the related
30 CB grafts in transplantation for adults with acute leukaemia, and to establish whether current graft-
31 genic model of tumorigenesis by Lmo2, T-cell acute leukaemias arise after an asymptomatic phase in wh
32 le explanation for the clusters of childhood acute leukaemias around the nuclear processing plants of
33 LL oncogene give rise to a highly aggressive acute leukaemia associated with poor clinical outcome.
34 in the E26 avian retrovirus which elicits an acute leukaemia by transforming haemopoietic progenitors
35 cohort of 71 diagnosis-relapse cases and 270 acute leukaemia cases that did not relapse found that 18
36 an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A
37 ss-of-function screen in an MLL-AF4-positive acute leukaemia cell line, we identify ENL as an unrecog
38 common entities encountered across lymphoma, acute leukaemia, chronic leukaemia, and multiple myeloma
41 markers useful in the classification of the acute leukaemias, especially the undifferentiated leukae
43 ingle agent oral OTX015 use in patients with acute leukaemia for further phase 2 studies is 80 mg on
44 mortality from haemorrhage in patients with acute leukaemia in the 1950s, the use of this therapy ha
45 ficient to cause embryonic stem cell-derived acute leukaemias in chimeric mice, and these tumours occ
46 diation as part of conditioning regimens for acute leukaemia is progressively declining because of co
49 cross haematological malignancies, including acute leukaemia, lymphoma, multiple myeloma, and myelopr
50 tional oncogenic mutations result in a fatal acute leukaemia made of proliferating immature cells.
51 aboratory adverse event rates for paediatric acute leukaemia; moreover, ExtractEHR seems to detect hi
52 sed or refractory acute myeloid leukaemia or acute leukaemia of ambiguous lineage with adequate organ
53 tors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that
54 of acute myeloid leukaemia, mixed phenotype acute leukaemia, or high-risk myelodysplastic syndrome (
55 utropenia and infection-related mortality in acute leukaemia patients and those receiving high dose c
56 ectopic expression of LMO1 or LMO2 in T cell acute leukaemias resulting from chromosomal translocatio
57 yltransferase MOZ is also rearranged in some acute leukaemias, resulting in the expression of MOZ fus
58 and joints, and salivary glands, as well as acute leukaemias, standardised incidence ratios exceeded
61 degradation of LMO2 in the context of T cell acute leukaemias (T-ALL) has therapeutic potential, a ch
62 tic cell neoplasm (BPDCN)-an unusual form of acute leukaemia that often presents with malignant cells
63 rch for other molecular abnormalities in the acute leukaemias that might serve as therapeutic targets
64 ce screening with functional analyses across acute leukaemias, we define a selective dependency on th
65 the importance of both LMO2 and HOX genes in acute leukaemias, we further demonstrated that the regul
66 data support the use of UCB for adults with acute leukaemia when there is no HLA-matched unrelated a
67 y reported a fusion protein NUP98-IQCG in an acute leukaemia, which functions as an aberrant regulato
70 clearance or alloreactivity in patients with acute leukaemia who received a myeloablative 10/10 HLA-m
71 This is a retrospective analysis from the Acute Leukaemia Working Party of the European Group for